Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$232.8MCash on Hand
82.9mo Cash Runway
Follow ANL by emailGet an email when ANL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ANL, unsubscribe in one click. Privacy
📣 What ANL Says Is Next
second half of 2027 · “We look forward to advancing this asset globally and remain on track to report full Phase Ia data in the second half of 2027.” This global phase I trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AN4035 as monotherapy and in combination with cetuximab in patients with CEACAM5-enriched, RAS-addicted solid tumors.”
Company press release, Sep 8, 2026 · SEC filing
2H26 · “AN4035: Dosing of first patient in global Phase I trial is expected in 2H26, with initial clinical data in 2H27”
Company press release, Aug 14, 2026 · SEC filing
1H27 · “AN9025: Initial Phase Ia clinical data from the QD arm, and possible early look at QW arm, are expected in 1H27”
Company press release, Aug 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 28, 2026 ·
Adlai Nortye announced an oral presentation on AN4035, a CEACAM5-targeting ADC with a pan-RAS(ON) inhibitor payload, at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 19. The talk will cover translational and EGFR combination data from the ongoing Phase I study. Form 6-K · SEC filing · Press release
Oct 15, 2026 ·
Deal Adlai Nortye signed clinical trial collaboration and supply agreements with Lilly and Merck KGaA, Darmstadt, Germany, under which both companies will supply cetuximab at no cost for its Phase I trial of AN4035 with cetuximab. The monotherapy and combination arms will start on a staggered timeline. Form 6-K · SEC filing · Press release
Sep 30, 2026 ·
Shareholder vote Extraordinary General Meeting held September 30, 2026 with a quorum of 40,433,365 of 193,193,810 ordinary shares present. All resolutions were passed, with full text previously filed on August 26, 2026. Form 6-K · SEC filing
Sep 30, 2026 ·
Leadership Adlai Nortye appointed Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu previously was a Managing Director of equity research at Lucid Capital Markets and a Director at Leerink Partners. Form 6-K · SEC filing · Press release
Sep 8, 2026 ·
Regulatory Adlai Nortye said its first patient was dosed in Australia for AN4035, a CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor, starting a global Phase I trial. The U.S. FDA issued a Study-May-Proceed letter on the IND, and the company expects full Phase Ia data in the second half of 2027. Form 6-K · SEC filing · Press release
Aug 26, 2026 ·
Shareholder vote Calls an extraordinary general meeting for September 30, 2026 in Singapore. Shareholders will vote on issuing up to 90,000,000 Class A Ordinary Shares, re-electing three directors and Shaorong Liu, appointing Wanjin Hong as independent director, and fixing director and auditor pay. Form 6-K · SEC filing · Press release
Aug 19, 2026 ·
Listing Completed a name change to Adlai Nortye Group Ltd., redomiciled from the Cayman Islands to Singapore, and moved its registered office on July 29, 2026. ADSs begin trading under the new name on August 21, 2026, with the ticker ANL and CUSIP unchanged. Form 6-K · SEC filing · Press release
Aug 14, 2026 ·
Earnings Reported unaudited first half 2026 results and pipeline progress. First patient dosed in the U.S. QW arm of the AN9025 pan-RAS(ON) Phase I trial in July 2026. Australian ethics approval received for AN4035 Phase I. Initial AN9025 data expected in 1H 2027. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jul 2027 · Phase 1 · Recruiting · An Initial Evaluation of AN8025 in Solid Tumors Registry primary completion date, not a results date
Jan 2028 · Phase 1 · Recruiting · Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations Registry primary completion date, not a results date
Dec 2028 · Phase 1 · Recruiting · A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not ANL's own candidates): Pembrolizumab, Leucovorin Calcium, Capecitabine, Atezolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ANL holds $232.8M in cash and short-term investments and burns about $8.4M/quarter from operations,
an estimated runway of 82.9 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.